Viz.ai Receives Edison Award for HCM Module
Summary
Viz HCM, the company’s AI software solution designed to detect and triage patients with signs of hypertrophic cardiomyopathy (HCM), was recognized in the Health Medical & Biotech category and Cardiovascular Health Diagnostics and Monitoring subcategory. The awards are widely recognized as one of the premier accolades that companies can receive in the name of innovation and business success. “We are honored to win our third, prestigious Edison Award, reaffirming our mission-critical work to transform AI-driven healthcare,” said Dr. Chris Mansi, CEO and co-founder of Viz.ai. The Viz HCM module, developed as part of a multi-year funding agreement between Viz.ai and Bristol Myers Squibb, was granted De Novo approval by the FDA in August 2023, creating a new regulatory category for cardiovascular machine learning-based notification software. The panel is composed of more than 2,000 senior business executives and academics from the fields of product development, design, engineering, science, marketing and education, as well as past winners.